Discordance Between Systemic Lupus Erythematosus Disease Activity Index Domain Weights and Their Association With Organ Damage Accrual

• by Kevin Zhang, Eric F. Morand, Sarah E. Boyd, François Petitjean, Alberta Hoi, Rachel Koelmeyer, Iolanda Miceli, Julie A. Monk, Hieu T. Nim

• May 12, 2026

The mirror of illness: identity, embodiment, and clinical care in systemic sclerosis

• by Neslihan Gokcen

• June 23, 2026

Reproducible Molecular Subtypes in Systemic Lupus Erythematosus Are Associated With Disease Activity, Serology, and Distinct Trajectories Over Time

• by Loqmane Seridi, Eugene Myshkin, Erika Noss, Sheng Gao, Julio Molineros, Carolyn Cuff, Dawn Waterworth, Matthew J. Loza

• July 1, 2026

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

• by Kathryn Wighton

• April 28, 2026

• 2 min